pixantrone has been researched along with Recrudescence in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 9 (81.82) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Bregni, M; de Barrenetxea Lekue, C; de Oteyza, JP; Grasso Cicala, S; Mombiedro, C; Navarro, B; Sancho, JM; Soler Campos, JA; Soler, B; Spione, M; Zinzani, PL | 1 |
| Argnani, L; Casadei, B; Malaspina, F; Pellegrini, C; Zinzani, PL | 1 |
| Blajer-Olszewska, B; Chojnacki, T; Drozd-Sokołowska, J; Długosz-Danecka, M; Hus, I; Jurczak, W; Jurczyszyn, A; Puła, B; Raźny, M; Romejko-Jarosińska, J; Taszner, M | 1 |
| Dunder, K; Flores, B; Gisselbrecht, C; Hudson, I; Laane, E; Péan, E; Pignatti, F; Salmonson, T; Sjöberg, J | 1 |
| Hay, N; Landells, LJ; Prescott, C; Stevens, A; Sutcliffe, F | 1 |
| Hatswell, AJ; Kadambi, A; Lanitis, T; Muszbek, N; Patel, D; Pettengell, R; Singer, JW; Wang, L | 1 |
| Ardeshna, K; Bailey, C; Chaidos, A; Collins, GP; Cwynarski, K; Eden, D; Eyre, DW; Eyre, TA; Hatton, CS; Jasani, P; Kothari, J; Linton, KM; Osborne, WL; Rohman, P; Rowntree, C; Shankara, P | 1 |
| Barosi, G; Corradini, P; Martelli, M; Minotti, G; Oliva, S; Spina, M; Tura, S; Zinzani, PL | 1 |
| Borchmann, P; Cernohous, P; Engert, A; Herbrecht, R; Hess, G; Morschhauser, F; Singer, JW; Veals, SA; Wilhelm, M | 1 |
| Cohen, GI; Fayad, LE; Kuepfer, C; Liebmann, JE; Modiano, MR; Pro, B; Romaguera, JE; Singer, JW; Srokowski, TP | 1 |
| Borchmann, P; Camboni, G; Engert, A; Gisselbrecht, C; Günther, H; Harousseau, JL; Morschhauser, F; Parry, A; Pfreundschuh, DM; Rudolph, C; Schnell, R; Wilhelm, M | 1 |
4 trial(s) available for pixantrone and Recrudescence
| Article | Year |
|---|---|
The Cost-effectiveness of Pixantrone for Third/Fourth-line Treatment of Aggressive Non-Hodgkin's Lymphoma.
Topics: Antineoplastic Agents; Cost-Benefit Analysis; Disease-Free Survival; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Quality-Adjusted Life Years; Recurrence; Retreatment; Secondary Prevention; Survival Rate; United Kingdom | 2016 |
Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Immunosuppressive Agents; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Prednisone; Recurrence; Survival Analysis; Treatment Outcome; Vincristine | 2011 |
Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: phase 1 study with a dose-expansion cohort.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Retreatment; Rituximab; Vidarabine | 2011 |
Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Drug Administration Schedule; Female; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Lymphopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Recurrence; Thrombocytopenia; Topoisomerase II Inhibitors; Treatment Outcome | 2003 |
7 other study(ies) available for pixantrone and Recrudescence
| Article | Year |
|---|---|
Efficacy and safety of pixantrone for the treatment of multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas.
Topics: Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Isoquinolines; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Prognosis; Recurrence; Retreatment; Retrospective Studies; Topoisomerase II Inhibitors; Treatment Outcome | 2020 |
Impressive Response to Pixantrone after Allogeneic Transplant in a Multiple Relapsed Diffuse Large B-Cell Lymphoma.
Topics: Adult; Antineoplastic Agents; Humans; Isoquinolines; Lymphoma, Large B-Cell, Diffuse; Male; Positron-Emission Tomography; Recurrence; Remission Induction; Salvage Therapy; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome | 2017 |
Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Poland; Recurrence; Retrospective Studies; Rituximab; Salvage Therapy; Transplantation, Autologous | 2019 |
The European Medicines Agency review of pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphomas: summary of the scientific assessment of the committee for medicinal products for human u
Topics: Adult; Anthracyclines; Drug Approval; European Union; Female; Humans; Isoquinolines; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Meta-Analysis as Topic; Recurrence; Risk Assessment; Treatment Outcome | 2013 |
NICE guidance on pixantrone monotherapy for multiply relapsed or refractory aggressive non-Hodgkin lymphoma.
Topics: Cost-Benefit Analysis; Drug Approval; Drug Costs; Drug Resistance, Neoplasm; Evidence-Based Medicine; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Practice Guidelines as Topic; Recurrence; Topoisomerase II Inhibitors; Treatment Outcome | 2014 |
Results of a multicentre UK-wide retrospective study evaluating the efficacy of pixantrone in relapsed, refractory diffuse large B cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cohort Studies; Disease-Free Survival; Female; Humans; Isoquinolines; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Topoisomerase II Inhibitors; Treatment Outcome; Young Adult | 2016 |
Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non-Hodgkin lymphoma: a SIE, SIES, and GITMO consensus paper.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease Management; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Practice Guidelines as Topic; Recurrence; Topoisomerase II Inhibitors | 2016 |